Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study.

Wei-Chen LinWei-Chen TaiChung-Hsin ChangChia-Hung TuI-Che FengMing-Jium ShiehChen-Shuan ChungHsu-Heng YenJen-Wei ChouJau-Min WongYu-Hwa LiuTien-Yu HuangChiao-Hsiung ChuangTzung-Jiun TsaiFeng-Fan ChiangChien-Yu LuWen-Hung HsuFang-Jung YuTe-Hsin ChaoDeng-Chyang WuAi-Sheng HoHung-Hsin LinChun-Lung FengKeng-Liang WuMing-Wun WongChien-Chih TungChun-Chi LinChia-Chang ChenHuang-Ming HuLung-Sheng LuHuann-Sheng WangI-Chen WuHsin-Yu KuoJia-Feng WuHsiang Yao ShihYen-Hsuan NiShu-Lun TangPeng-Hsu ChenShu Chen Wei

Published in: Inflammatory bowel diseases (2023)

The findings demonstrated VDZ effectiveness in IBD patients in Taiwan, with high treatment persistence rates and favorable safety profiles. A substantial IBD relapse rate was observed in patients who had mandatory drug holiday.

Keyphrases

ulcerative colitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
systematic review
prognostic factors
cross sectional
smoking cessation